These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 31499391)
21. Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis. Girshkin L; Matheson SL; Shepherd AM; Green MJ Psychoneuroendocrinology; 2014 Nov; 49():187-206. PubMed ID: 25108162 [TBL] [Abstract][Full Text] [Related]
22. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone. Lenze EJ; Hershey T; Newcomer JW; Karp JF; Blumberger D; Anger J; Doré P; Dixon D Int J Geriatr Psychiatry; 2014 Sep; 29(9):962-9. PubMed ID: 24633761 [TBL] [Abstract][Full Text] [Related]
23. The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa. Bou Khalil R; Souaiby L; Farès N Physiol Behav; 2017 Mar; 171():13-20. PubMed ID: 28043861 [TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid sensitivity in mood disorders. Spijker AT; van Rossum EF Neuroendocrinology; 2012; 95(3):179-86. PubMed ID: 22076031 [TBL] [Abstract][Full Text] [Related]
25. Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability. Gupta S; Aslakson E; Gurbaxani BM; Vernon SD Theor Biol Med Model; 2007 Feb; 4():8. PubMed ID: 17300722 [TBL] [Abstract][Full Text] [Related]
26. Clinical and biological effects of mifepristone treatment for psychotic depression. Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710 [TBL] [Abstract][Full Text] [Related]
27. Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis. Jain FA; Connolly CG; Reus VI; Meyerhoff DJ; Yang TT; Mellon SH; Mackin S; Hough CM; Morford A; Wolkowitz OM Psychoneuroendocrinology; 2019 Nov; 109():104386. PubMed ID: 31382170 [TBL] [Abstract][Full Text] [Related]
28. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Nikisch G; Mathé AA; Czernik A; Thiele J; Bohner J; Eap CB; Agren H; Baumann P Psychopharmacology (Berl); 2005 Oct; 181(4):751-60. PubMed ID: 15988572 [TBL] [Abstract][Full Text] [Related]
29. Hypothalamic-pituitary-adrenal (HPA) axis functioning as predictor of antidepressant response-Meta-analysis. Fischer S; Macare C; Cleare AJ Neurosci Biobehav Rev; 2017 Dec; 83():200-211. PubMed ID: 29032090 [TBL] [Abstract][Full Text] [Related]
30. Mineralocorticoid receptor function in major depression. Young EA; Lopez JF; Murphy-Weinberg V; Watson SJ; Akil H Arch Gen Psychiatry; 2003 Jan; 60(1):24-8. PubMed ID: 12511169 [TBL] [Abstract][Full Text] [Related]
31. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874 [TBL] [Abstract][Full Text] [Related]
32. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Watson S; Gallagher P; Porter RJ; Smith MS; Herron LJ; Bulmer S; ; Young AH; Ferrier IN Biol Psychiatry; 2012 Dec; 72(11):943-9. PubMed ID: 22770649 [TBL] [Abstract][Full Text] [Related]
33. The impact of treatment on HPA axis activity in unipolar major depression. McKay MS; Zakzanis KK J Psychiatr Res; 2010 Feb; 44(3):183-92. PubMed ID: 19747693 [TBL] [Abstract][Full Text] [Related]
34. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. Cleare AJ; Miell J; Heap E; Sookdeo S; Young L; Malhi GS; O'Keane V J Clin Endocrinol Metab; 2001 Aug; 86(8):3545-54. PubMed ID: 11502777 [TBL] [Abstract][Full Text] [Related]
35. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function. Nikisch G Neuro Endocrinol Lett; 2009 Mar; 30(1):11-6. PubMed ID: 19300389 [TBL] [Abstract][Full Text] [Related]
36. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Buckley TM; Mullen BC; Schatzberg AF Psychoneuroendocrinology; 2007; 32(8-10):859-64. PubMed ID: 17666187 [TBL] [Abstract][Full Text] [Related]
38. Overnight suppression of HPA axis after mineraolocorticoid receptor stimulation: A sleep endocrine study. Demiralay C; Agorastos A; Jahn H; Kellner M; Yassouridis A; Wiedemann K Psychiatry Res; 2015 May; 227(1):65-70. PubMed ID: 25799272 [TBL] [Abstract][Full Text] [Related]
39. Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study. Ventura-Juncá R; Symon A; López P; Fiedler JL; Rojas G; Heskia C; Lara P; Marín F; Guajardo V; Araya AV; Sasso J; Herrera L BMC Psychiatry; 2014 Aug; 14():220. PubMed ID: 25086452 [TBL] [Abstract][Full Text] [Related]
40. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Pariante CM Ann N Y Acad Sci; 2009 Oct; 1179():144-52. PubMed ID: 19906237 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]